Naason Science NEWS

Osong, South Korea  2023-09-21

Naason Science to participate in COGNI+; an Addex Therapeutics Ltd.-led consortium to explore the effects of Addex’s MGLU2 NAM program in mild neurocognitive disorder (mNCD).

Naason Science Inc. (Republic of South Korea), a preclinical contract, and collaborative, research company announced participation in the Addex Therapeutics’ (Geneva, Switzerland) consortium that has been awarded a €4 million Eurostars grant. This program directly supports Addex’s metabotropic glutamate 2 (mGlu2) receptor-negative allosteric modulator (NAM) program for mild neurocognitive disorder (mNCD). The project, named COGNI+, has been instituted in order to deliver clinical candidates for IND-enabling studies. The consortium includes Naason Science (South Korea), BioAxis Research (Netherlands), Pharmidex Pharmaceutical Services (UK), and Stichting Radboud Universiteit (Netherlands).

For additional information please contact info@naasonscience.com

About Naason Science:

Naason Science has quickly become a global leader in contract and collaborative research aimed at preclinical drug development in a variety of therapeutic areas. Naason´s various preclinical modeling platforms are customized to suit the needs of drug developers. The platforms can accommodate all drug delivery routes as well as preclinical proof-of-concept for medical devices. From in vitro systems to large and small animal in vivo models Naason Science provides a toolbox of state-of-the-art technologies that allow for rapid and effective testing of preclinical drug candidates quickly and a lower overall cost to drug discoverers. ​​

For more information please see the announcement

May 7, 2023 - Osong, Republic of South Korea; Edinburgh, United Kingdom

Naason Science Ltd. shows presence and support for those suffering from endometriosis by attending the World Congress of Endometriosis in Edinburgh, Scotland.

Women’s health and genitourinary health issues remain a largely unmet need on a global scale. Naason Science, its scientific and technical staff, along with its comprehensive preclinical drug development capabilities are committed to continued support for this community through preclinical research.

Recently in Edinburgh at the World Endometriosis Congress Naason Science attended workshops and presentations as well as chairing a session of presentations outlining some of the newer experimental drug treatments aimed at endometriosis.

Naason Science’s CEO Dr Larry Chong Park teamed up with Professor Christian Becker (Oxford University) to chair a session on potential new therapies for endometriosis. It was a great opportunity to hear the thoughts on what may be on the horizon for the treatment of endometriosis in the future. The presentations were thoroughly enjoyable and thought provoking.

While addressing the responses as well as the drug discovery community present during the sessions Dr Larry Park, Naason Science CEO said, “we are very happy to be able to receive and comment on the information provided by those presenting the data for these possible future therapies aimed at endometriosis. Despite my 25 years as a drug discoverer, I am always interested in how others see the route forward for certain technologies. It is obvious to us at Naason that the world endometriosis community is committed to finding new ways to tackle this potentially debilitating disease and this only makes Naason just as committed. Therefore, it is important that we remain in touch with developers as well as those advocating for increasing the amount of research and research funding into this disease area. The work that Naason continues to do the area of endometriosis is currently unmat5hced in the preclinical sector and we will increase this over the coming year.”

Naason science thanks all of the attendees with whom we met as well as all of those who presented their data and ideas at the WCE in Edinburgh.

December 16, 2022  - Naason Science won the Presidential Commendation in the Entrepreneurship Division in the field of Entrepreneurship Revitalization at the '2022 Venture Startup Promotion Awards Ceremony'.

The Venture Startup Promotion Awards Ceremony, which was held on the 15th of December, is an annual event hosted by the Ministry of SMEs and Startups to discover and encourage excellent venture companies and start-ups that lead innovative growth. Awards were given to ventures, start-ups, investment, and support institutions that contributed to job creation and industrial development this year.

Article: http://www.jbnews.com/news/articleView.html?idxno=1379318

Published 2019-08-10

Naason Science has recently completed validation of the models within it’s Orthopedic modelling platform. These models include models for primary and secondary (post-traumatic, congenital etc.) OA. All models can combine MRI and CT micro-CT. The models are available in a variety of species.

The models are:

▪ Surgical model for ACLT

▪ Surgical model for Meniscectomy (MMT)

▪ Collagenase Injection

▪ Sodium monoiodoacetate /MIA

▪ Crystallin alpha B KO mouse model

The models can incorporate histopathology and biochemical analysis as we all as imaging as well as 24/7 home-cage monitoring for:

▪ General locomotion

▪ Circadian Rythm

▪ Temperature

▪ Anticipatory behaviour

▪ Social distancing – anxiety & depression

▪ Climbing/rearing behaviour

▪ Gait Analysis

▪ Feeding/drinking

▪ Grooming​

For more information about our Modelling Platform for Osteoarthritis please contact info@naasonscience.com.